Tarsus Pharmaceuticals, Inc.
TARS
Classement en actions
#4589
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Prix de l'action
$71.12
Capitalisation boursière
$3.33B
Changement (1 jour)
2.33%
Changement (1 an)
-0.10%
Pays
US
Échange Tarsus Pharmaceuticals, Inc. (TARS)
Catégorie
Healthcare
Ratio P/S pour Tarsus Pharmaceuticals, Inc. (TARS)
Ratio P/S au October 2026 TTM : 5.13
Selon les derniers rapports financiers et le cours de l'action de Tarsus Pharmaceuticals, Inc., le ratio cours/ventes actuel (TTM) est 5.13. À la fin de 2023, le ratio P/S était de 34.10.
Historique du ratio P/S pour Tarsus Pharmaceuticals, Inc. de 2018 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| 2026 (TTM) | 5.13 | -54.93% |
| 2024 | 11.38 | -66.63% |
| 2023 | 34.10 | 143.94% |
| 2022 | 13.98 | 72.40% |
| 2021 | 8.11 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| 10.02 | 95.38% |
US
|
|
| 40.55 | 690.54% |
US
|
|
| 3.96 | -22.78% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 97.80% |
NL
|
